bluuebunny/crossref_metadata_2025_split huggingface dataset:
Clinical symptomatology and theory of mind in schizophrenia: Which relationship?
Authors: Mrizak J. , Trabelsi R. , Arous A. , Aissa A. , Ben Ammar H. , El Hechmi Z. 
Published: May 2016

IntroductionTheory of mind (ToM) has repeatedly been shown to be compromised in many patients with schizophrenia (SCZ). It now seems to be quite well-established that patients with profound negative or disorganized symptoms perform poorly on ToM tasks. By contrast, findings in patients with predominant positive symptoms are much more ambiguous.ObjectivesTo investigate the relationship between ToM deficits and different symptoms dimensions in SCZ.MethodsFifty-eight outpatients with stable SCZ completed the intention-inferencing task (IIT), in which the ability to infer a character's intentions from 28 short comic strip stories is assessed. Symptomatology evaluation comprised the Positive and Negative Syndrome Scale (PANSS), the Calgary Depression Scale for Schizophrenia (CDSS) and the Clinical Global Impressions Scale Improvement and severity (CGI).ResultsThe number of correct answers in the IIT negatively correlated with both the positive (P = 0.015) and negative (P < 0.0001) scales of the PANSS. ToM deficits were correlated with the conceptual disorganization, hallucinations and the suspiciousness/persecution items.The patients who had more false answers in the IIT also had significantly higher scores at the positive (P = 0.005), negative (P < 0.0001) and general (P < 0.0001) scales of the PANSS. Worse IIT performance correlated with a higher severity index in the CGI. No correlations were found between IIT scores and CDSS scores.ConclusionsOur results confirm the relationship between ToM deficits and negative symtomps and suggest that ToM may also be correlated to specific positive symptoms.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Basic symptoms as subjective cognitive deficit in schizophrenia: Cognitive, clinical and functional associations
Authors: Vargas M.L. , López-Lorenzo S. , Legascue I. , Nagore A. , Serrano P. , Jimeno-Bulnes N. 
Published: May 2016

IntroductionBasic symptoms are subjective complaints that present at the early states in psychotic disorders and persist in the long-term. They can be studied using hetero applied clinical instruments or self-administered questionnaires. Basic symptoms can be useful as screening tools in at risk populations.AimsTo determine if basic symptoms (subjective cognitive deficits) are associated with the objectively measured cognitive deficit after controlling for functioning and symptomatology.MethodsOne observational, transversal, psychopathological and neuropsychological study was performed on a schizophrenia outpatients sample (n = 78). Correlations were measured by using Spearman's Rho coefficient. Basic symptoms were registered by using the Frankfurt Complaints Questionnaire (FCQ-3); cognitive status was assessed by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); clinical status was assessed by PANSS and Clinical Global Impression (CGI); functional status was measured with Global Assessment of Functioning (GAF).ResultsAll the dimensions were related to subjective complaints: cognitive functioning (r = −.38; P < .001); positive symptoms (r = .54; P < .001); negative symptoms (r = .26; P < .02); general symptoms (r = .41; P < .001); CGI (r = .57; P < .001); GAF (r = −.45; P < .001). The association between subjective and objective cognitive deficit remains significative after controlling for the clinical and functional variables, except when controlling for CGI.ConclusionsThe evaluation of basic symptoms with FCQ-3 is related with an objective cognitive deficit and could be useful as a screening tool.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Association between patient's personality traits and outcome of hospital treatment of opioid addiction
Authors: Delic M. , Kajdiž K. , Pregelj P. 
Published: May 2016

IntroductionDespite different treatment approaches many drug addicted patients continue to use drugs during and after treatment.ObjectivesPersonality traits are considered risk factors for drug use, and, in turn, the psychoactive substances impact individuals’ traits.AimsTo describe the sample of 186 opioid addicted patients entered hospital treatment and assessing the differences in personality traits between abstinent and non-abstinent after one year.MethodsA cohort of 186 patients consecutively admitted to the detoxification unit was investigated. The research interview, the Big Five Inventory (BFI), the Treatment Outcomes Profile (TOP) were administered during the first week of admission to the detoxification unit. Urine test was administered on the day of admission and at each follow-up point in combination with the TOP (after three, six and twelve months). Illicit drugs abstinence during one year after intake was selected as a treatment outcome measure.ResultsTwelve months after admission 82 (44.9%) patients abstained completely. Agreeable patients remain in treatment longer (r = 0.20, P = 0.07). Extraversion and openness are negatively correlated with abstinence after six and twelve months (r = –0.15, P = 0.041; r = –0.15, P = 0.044). Neuroticism is in negative correlation with duration of treatment (r = –0.20, P = 0.006). Patients who are less open to new experiences are more likely to abstain from drugs 6 months after admission (r = –0.17, P = 0.021).ConclusionPersonality measured with BFI correlates with treatment outcome poorly. At the same time personality could have an important role in responding to treatment, but personality traits could be at the same time protective as well as risk factors.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Results of a smoking cessation program in primary care
Authors: de la Red Gallego H. , González Silva Y. , Montero Carretero T. , Delgado de Paz Á. , Sánchez Añorga M.F. , Cañibano Maroto E. , Isidro García G. , Álvarez Astorga A. , Alonso Sánchez A. , Martín Fernández M. , Álvarez Hodel A. , Pérez González I. , Nieto Sánchez S. , Calvo Sardón S. , González Gurdiel I. , Hernández Antón R. , Gómez Sánchez S. , Noval Canga C. , Hernández García M.S. , Rodríguez Andrés L. 
Published: May 2016

IntroductionSmoking is an addictive and chronic disease. Twenty-four percent of the Spanish population in 2012 smoked daily.Aims and objectivesTo evaluate a smoking cessation program in a Primary Care Center.MethodsObservational, prospective study. We describe an individualized smoking cessation in Plaza del Ejército Health Center (Valladolid). Inclusion criteria: active smoker, ≥ 18 years old and belonging to the Health Center. Exclusion: severe mental illness. Included patients from November 2013 until January2014. Ended in July 2014. Four Medical residents participated, we present the results of one of them. During the first consultation motivational interviewing was conducted, physical examination and treatment was prescribed (cognitive behavioral therapy or drug treatment: varenicline). In subsequent consultations interview and follow-up. Variables: age, gender, pack-years, nicotine dependence (Fagerstrom) and Prochaska and DiClemente phase, weight, treatment used, dropout rate and final withdrawal of snuff.ResultsEleven patients, mean age 48.18 (13.61), 7 (63.6) women. Comorbidity: 6 (54.5) anxious-depressive pathology, 1 (9.1) dysthymia, 2 (18.2) endocrine pathology and 1 (9.1) respiratory disease. Four (36.4) showed high dependency and 2 (18.2) extreme. Media packages 20.50/year (19,20). Seven (63.6) were in action phase of Prochaska and DiClemente and 2 (18.2) in preparation. Visits range: 1-11. The average was 4.55 (3.64). Three (27.27) patients attended only the first visit. Four (36.4) achieved complete abstinence, 3 (27.27) met maintenance phase. One (9.1) reduced consumption in half. Patients gained average 0.5 kg (2.47).ConclusionsThe results are similar to those reported in other series. Modest dropout rate. No pharmacological treatment was used due to high coexistence of comorbidities, the only patient who used varenicline suffered insomnia. Average age and media packages were superior to other series.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Depression, anxiety and panic disorders in chronic obstructive pulmonary disease: Correlations with disease severity and quality of life
Authors: Gherghesanu R. , Trofor L. , Pascal I.O. , Chirita R. , Frunza A. 
Published: May 2016

IntroductionDepression, anxiety and panic disorders are often encountered in chronic respiratory disorders, like chronic obstructive pulmonary disease (COPD), especially in severe disease stages with impaired quality of life.AimTo assess anxiety, depression and panic disorders among patients diagnosed with COPD and to correlate them with respiratory disease severity and quality of life.Material and methodWe investigated the profile of anxiety, depression and panic attacks in relation to patients’ medical history, demographic data, smoking status, COPD staging and disease severity (estimated by CAT quality of life questionnaire, GOLD guideline staging).ResultsA total of 60 COPD patients were enrolled. Smoking profile showed more intensive smoking in men (35.81 mean packs-years versus 24.38 in women). The COPD high-risk group type D was predominant, with severe dyspnea, decreased lung function, frequent exacerbations and low quality of life (mean CAT score: 21.75). Mean distribution of anxiety and depression symptoms among COPD subjects was corresponding to a 10.65 ± 3.54 SD anxiety score, respectively to 9.93 ± 3.80 SD depression score. Panic attacks were found in 43.3% of the patients.ConclusionsAnxiety, depression and panic attacks were frequent findings among severe, unstable COPD patients. More carefully screening for anxiety, depression and panic attacks in this category of patients, thus adding a specific psychotherapeutic component to the COPD general treatment plan, would improve patients’ health benefits.Disclosure of interestThe authors have not supplied their declaration of competing interest.
The relationship between previous trauma and alcohol and substance misuse in women
Authors: Husain M. , Moosa K. , Khan K. 
Published: May 2016

IntroductionThe association between previous trauma and the development of alcohol and substance misuse is well established, however, much of the research is focused on the association of PTSD with alcohol and substance misuse. This research will be focussing on trauma in general and its influence on the development of alcohol and substance misuse in women.ObjectivesThe main objective of this study was to investigate the relationship between previous traumatic events and the development of alcohol and substance misuse in women.MethodsThis was a retrospective case note study of 146 female patients from a UK based detoxification and rehabilitation centre. Trauma history from patient files were audited, with the trauma experienced being assigned a category.ResultsOut of 146 women with alcohol and/or substance misuse, 132 (90%) had experienced a previous trauma. The types of trauma experienced include; domestic (53%), traumatic grief (36%), sexual abuse (35%), physical (15%), bullying (4%) and neglect (4%). These results show that women who suffer from alcohol/substance misuse are highly likely to have suffered a previous trauma.ConclusionsThe results from this study suggest that women who have suffered previous trauma are high risk for alcohol and substance misuse problems, therefore early intervention and a robust psychological support system should be provided to women who have a history of trauma. Furthermore in addition to addiction treatment and behaviour focused therapy already in place trauma focussed therapy may prove beneficial.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Association between circadian rhythm, sleep disturbances and temperament in major depression, bipolar disorder and schizophrenia
Authors: Tunç S. , Yağcı İ. , Yenilmez Bilgin Y. , Canbek Ö. , Atagün M.İ. , Hüseyinoğlu N. , Ardıç S. 
Published: May 2016

IntroductionCircadian rhythms and quality of sleep have been associated with temperament characteristics in healthy populations. Since temperaments are personality traits concerning the behavioral, motivational and emotional responses, adaptive capacity for sleep and circadian rhythm may also be related with temperament traits.AimsTo identify the determinants of sleep quality (SQ) and biological rhythm (BR) in bipolar disorder, schizophrenia and depression among temperament measures.MethodsPatients with bipolar disorder (BD, n = 49), major depression (MD, n = 35), schizophrenia (SZ, n = 30) and a healthy control group (HC, n = 36) were enrolled. Pittsburgh Sleep Quality Index (PSQI), Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN) and the Temperament and Character Inventory (TCI) were the measures. One-way ANOVA, Spearman Correlation Test and Linear Regression analyses were the other comparisons.ResultsDeterminants of sleep quality were self-directedness in MD [F(1,26) = 6.10, P = 0.020] and BD [F(1,31) = 10.88, P = 0.002] groups. Self-transcendence (P = 0.004), self-directedness (P = 0.038) and persistence (P = 0.05) were the determinants of sleep quality in schizophrenia group [F(3,21) = 9.71, P < 0.001]. Harm-avoidance was the determinant of sleep quality in the HC group [F(1,28) = 7.97, P < 0.001]. Determinants of biological rhythms were harm-avoidance in the BD group [F(1,32) = 9.65, P = 0.004] and self-directedness in the SZ group [F(1,23) = 11.09, P = 0.003] and harm-avoidance (P < 0.001) and self-transcendence (P = 0.039) in the HC group [F(2,27) = 15.81, P < 0.001].ConclusionsSelf-Directedness was associated with circadian rhythm and sleep quality in MD, BD and SZ groups. Extreme temperament features may contribute to emotional and behavioral dysfunction, which may lead to abnormal sleep patterns in psychiatric disorders.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Gamma-hydroxybutyrate (GHB) withdrawal syndrome: First case report in Lithuania (Kaunas addiction treatment center)
Authors: Jucys K. , Leleikiene A. , Jokuboonis D. 
Published: May 2016

Gamma-hydroxybutyrate (GHB) is a γ-aminobutyric acid (GABA) precursor and metabolite that naturally occurs in the human body. Initially, GHB was used as an anaesthetic agent but was later also found to have anabolic, hypnotic, antidepressant, anxiolytic as well as cholesterol lowering effects. Recently though, research into GHB has been carried out primarily in assessing its effectiveness in treating alcohol and opioid withdrawal syndrome. There are no epidemiological data about GHB consumption in Lithuania, however during last decade there were observed many fatal cases of GHB users due to GHB intoxication or withdrawal abroad. In this article we will present the clinical case and problems which face the patient of 2-year daily GHB consumption. There were observed mild to moderate abstinence state presented with its clinical course and peculiarities. Whereas using GHB is becoming more popular in Lithuania, it is very important to pay attention to this substance and problems related to its usage.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Qualitative study of patients with dual pathology in treatment with aripiprazole extended-release injectable suspension
Authors: Fernández Mayo L. , Baño Rodrigo D. , Barbero García E. , Agujetas Rodriguez M. 
Published: May 2016

IntroductionStudies describe patients with dual pathology as subjects with worse clinical evolution and worse therapeutic response. These subjects have high percentages of worse therapeutic compliance and low adherence to psychopharmacological treatment. The conventional antipsychotics can induce dysphoria and worse craving and drug use. The long duration-injectable antipsychotics could serve as a good therapeutic alternative because they combine efficacy and tolerability.ObjectivesWe analyzed subjects treated with aripiprazole injectable to demonstrate its effectiveness on symptomatology, the reduction of craving and consumption of substances.Materials and methodsWe studied subjects with dual disorders at a Center for Attention to drug addicts treated with aripiprazole extended-release injectable. All of them met criteria for the diagnosis of disorders for cannabis and cocaine use. All of them had been previously treated with oral antipsychotics and/or injectable of long duration. Evolution of craving and consumption were evaluated through clinical interviews and urine analysis.ResultsCannabis was the main substance for all the patients. Three of them also often abused of cocaine. All of them were taking other treatments previously. The main causes of the change were: side effects and/or poor compliance. Only one patient discontinued follow-up. The rest of them showed good therapeutic adherence and better tolerability with aripiprazole injectable. The monthly dose was 400 mg.ConclusionsAripiprazole extended-release injectable is a good choice for dual disorders. A good therapeutic adherence involves not only a psychopathological improvement but also respect to craving and consumption, which makes aripiprazole injectable a suitable therapeutic option.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Aripiprazole oral treatment in a sample of patients with dual diagnosis
Authors: Llanes Álvarez C. , San Román Uría A. , Caldero Alonso A. , Garzón de Paz M.Á. , Franco Martín M.Á. 
Published: May 2016

IntroductionAripiprazole is the firstborn of the new dynasty of antipsychotic called third generation or neuromodulator of dopamine-serotonin system. It has proven to be an effective and well-tolerated antipsychotic. Dual Pathology represents the presence of comorbidity between mental illness and substance use disorders. It is an under-diagnosed problem and it is increasing frequency.ObjectivesThe aim of this study was to determine and describe the clinical profile of the patients admitted to the Dual Pathology Unit (UPD) at The Montalvos Hospital (Part of Salamanca University Teaching Hospital, Spain) treated with oral Aripiprazole.MethodsDescriptive, observational, retrospective study of a sample of patients admitted to the UPD to which oral aripiprazole was prescribed during hospitalization. A number of sociodemographic, clinical, and treatment-related variables are described.ResultsFrom a sample of 25 patients and according to DSM-5 criteria (APA, 2013) main diagnoses were: 14 cases of substance-induced psychotic disorder, 3 cases of schizophrenia; 3 cases of schizoaffective disorder; 2 cases of bipolar disorder; 1 case of schizophreniform disorder; 1 case of borderline personality disorder; 1 case of personality syndrome. The most used drugs before the admittance were cocaine, cannabis and opioids. The average dose of aripiprazole was 9 mg and no side effects or drug interactions were reported.ConclusionsApart from its well known efficacy in treament of psychosis, oral aripiprazole may be a first line treatment for Dual diagnosis patients, specially those with problems of non-compliance, due to high level prolactine side effects.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Cannabinoid hyperemesis syndrome
Authors: López-Romeo S. , Ledesma-Iparraguirre G. 
Published: May 2016

Case reportA 25-year-old man was attended in multiple times at Emergency Department by referring abdominal pain and vomiting. No organic disease was found and he was referred to Psychiatric Emergency to assess him. He had history of cannabis use (4–5 times/day) during last 5 years. He referred recurrent episodes of abdominal pain and vomiting since 4 years ago, he had found that having hot showers alleviate his symptoms. Urine screening was positive for THC and negative for other drugs. In results of blood tests, abdominal X-ray, abdominal ultrasonography, abdominal tomography and fibrogastroscopy didn’t find any abnormality. He was diagnosed from suffering a somatoform disorder. Treatment with Setraline 50 mg/day was prescribed and cannabis abstinence was recommended. He was referred to Mental Health outpatient service. He maintained cannabis abstinence for 1 month and some symptoms disappeared. However, 2 months later, he relapsed in cannabis use and all symptoms reappeared. Later he achieved cannabis abstinence again and he got full recovery, then he was diagnosed from cannabinoid hyperemesis syndrome.ConclusionCannabinoid hyperemesis syndrome is characterized by recurrent nausea, vomiting and colicky abdominal pain in patients with long-term cannabis use. These symptoms have been reported to be alleviated temporarily by taking a hot shower or more permanently by abstaining from the use of cannabis. The phenomenon of cannabinoid hyperemesis and clinical diagnosis remained obscure until recently. For this reason, it is necessary to take it into account in order to recognize it and help provide these patients early and better approach.Disclosure of interestThe authors have not supplied their declaration of competing interest.
The experience of using synthetic cannabinoids: A qualitative analysis of online user self-reports
Authors: Newman M. , Denton G. , Walker T. , Grewal J. 
Published: May 2016

IntroductionThe number of novel psychoactive substances (NPS) available is increasing. Synthetic cannabinoids (SC) are one of many NPS sold. SC aim to emulate the effects of natural cannabis by acting on cannabinoid receptors. Despite much research into pharmacology, there is limited data on the user experience of SC.AimIt is useful for psychiatrists, to understand what experiences people have whilst on illicit substances. The aim of this qualitative study is to gain an initial understanding of what characterizes the experiences of those who use SC.MethodFourty anonymously written online reports were collected from the “Erowid experience vaults” and analysed using the Empirical Phenomenological Psychological Method.ResultsThe analysis yielded 488 meaning units (MU). These were grouped into 36 categories revealing 5 broad themes: (1) physical affects; (2) sensory distortions and distortions of perception; (3) emotional and psychological effects; (4) re-dosing, addiction and comedown effects; (5) similarities to other substances.ConclusionSynthetic cannabinoids have a mixed effect on users with a myriad of experiences reported. Some experienced positive results from their usage such as euphoria and relaxation, however these were counter balanced by those who experienced some serious negative emotional and physical side effects such as anxiety, paranoia, palpitations and convulsions. SC appear to often emulate that of their natural counterpart, yet there is an unpredictability to them which can end with serious consequences. Online forum content gives us a strong base understanding of users experiences of SC. Further research is required to elucidate a more nuanced understanding.Disclosure of interestThe authors have not supplied their declaration of competing interest.